Table 5.

Scoring model for the prediction of non-AIDS-defining cancers (NADCs) in HIV-infected patients (N = 1001)

Score	No. of NADCs/ Non-NADCs	Cumulative incidence rate of NADCs at 5 years (95% CI)	Cumulative incidence rate of NADCs at 10 years (95% CI)	Hazard ratio (95% CI)
0	2/ 222	0.9 (0.2–3.7)	0.9 (0.2–3.7)	1 (reference)
1	1/ 91	0	1.4 (0.2–9.7)	0.9 (0.08–10.2)
2	6/ 273	0.4 (0.1–2.8)	1.4 (0.4–4.4)	2.5 (0.5–12.3)
3	8/ 174	2.9 (1.2–6.9)	2.9 (1.2–6.9)	5.1 (1.1–23.9)
4	11/ 101	5.8 (2.7–12.5)	10.7 (5.5–20.4)	12.6 (2.8–56.7)
≥5	33/ 79	20.2 (13.5–29.7)	41.3 (29.7–55.3)	53.2 (12.7–222.5)
Total	61/ 940			P for trend < 0.001

C-statistics: 0.8 (95%CI, 0.8–0.9, P < 0.001)

Note. Based on the final model’s regression coefficients (Table 4), 1 point each was assigned to blood transmission, and HBV, 2 points each were assigned to age 40–49, smoker, and IDU, 3 points was assigned to age 50–59, age 60–69, and 4 points was assigned to age ≥ 70. Abbreviations: CI confidence interval, HBV hepatitis B virus, IDU injection drug use, NADCs non-AIDS-defining cancers